NASDAQ:CHRSCoherus Biosciences Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Coherus Biosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $18.21 +0.62 (+3.52 %) (As of 08/3/2020 02:12 PM ET) Add Compare Share Today's Range$17.53Now: $18.21▼$18.4150-Day Range$16.08MA: $17.72▼$18.9252-Week Range$10.86Now: $18.21▼$23.91Volume20,394 shsAverage Volume936,051 shsMarket Capitalization$1.29 billionP/E Ratio9.29Dividend YieldN/ABeta2.03 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Coherus BioSciences, Inc., a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte-colony stimulating factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States. Its clinical-stage product candidates include immunology, anti-tumor necrosis factor biosimilar candidates, CHS-1420 for adalimumab and CHS-0214 for etanercept, which has completed Phase III clinical programs; ophthalmology biosimilar candidates, CHS-3351 for ranibizumab and CHS-2020 for aflibercept that is in preclinical development; and CHS-131, small molecule therapeutic candidate and other metabolic conditions. Coherus BioSciences, Inc. has collaboration and license agreements with Daiichi Sankyo Company, Limited; Baxalta Incorporated; Baxalta US Inc.; Baxalta GmbH; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingCoherus Biosciences has received a consensus rating of Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $29.78, Coherus Biosciences has a potential upside of 63.0% from its current price of $18.27.Amount of Analyst CoverageCoherus Biosciences has only been the subject of 4 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesCoherus Biosciences has received 396 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCoherus Biosciences has received 381 “underperform” votes. (Add your “underperform” vote.)Community SentimentCoherus Biosciences has received 50.97% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Coherus Biosciences and other stocks. Vote “Outperform” if you believe CHRS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CHRS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCoherus Biosciences does not currently pay a dividend.Dividend GrowthCoherus Biosciences does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Coherus Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,736,217.00 in company stock.Percentage Held by InsidersOnly 15.86% of the stock of Coherus Biosciences is held by insiders. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Coherus Biosciences are expected to decrease by -39.84% in the coming year, from $1.28 to $0.77 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Coherus Biosciences is 9.32, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 16.41.Price to Earnings Ratio vs. SectorThe P/E ratio of Coherus Biosciences is 9.32, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 25.26.Price to Earnings Growth RatioCoherus Biosciences has a PEG Ratio of 2.34. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioCoherus Biosciences has a P/B Ratio of 12.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.43 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CHRS Previous Symbol CUSIPN/A CIK1512762 Webwww.coherus.com Phone650-649-3530Debt Debt-to-Equity Ratio1.21 Current Ratio3.32 Quick Ratio3.18Price-To-Earnings Trailing P/E Ratio9.29 Forward P/E Ratio14.23 P/E Growth2.34 Sales & Book Value Annual Sales$356.07 million Price / Sales3.63 Cash Flow$1.37 per share Price / Cash Flow13.25 Book Value$1.50 per share Price / Book12.14Profitability EPS (Most Recent Fiscal Year)$1.23 Net Income$89.83 million Net Margins33.42% Return on Equity190.82% Return on Assets41.58%Miscellaneous Employees232 Outstanding Shares70,910,000Market Cap$1.29 billion Next Earnings Date8/6/2020 (Confirmed) OptionableOptionable $18.21 +0.62 (+3.52 %) (As of 08/3/2020 02:12 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive CHRS News and Ratings via Email Sign-up to receive the latest news and ratings for CHRS and its competitors with MarketBeat's FREE daily newsletter. Coherus Biosciences (NASDAQ:CHRS) Frequently Asked Questions How has Coherus Biosciences' stock been impacted by COVID-19 (Coronavirus)? Coherus Biosciences' stock was trading at $15.87 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CHRS stock has increased by 14.7% and is now trading at $18.21. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Coherus Biosciences? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Coherus Biosciences in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Coherus Biosciences. When is Coherus Biosciences' next earnings date? Coherus Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Coherus Biosciences. How can I listen to Coherus Biosciences' earnings call? Coherus Biosciences will be holding an earnings conference call on Thursday, August 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available. How were Coherus Biosciences' earnings last quarter? Coherus Biosciences Inc (NASDAQ:CHRS) issued its quarterly earnings results on Thursday, May, 7th. The biotechnology company reported $0.54 EPS for the quarter, topping the Zacks' consensus estimate of $0.44 by $0.10. The biotechnology company had revenue of $116.18 million for the quarter, compared to analysts' expectations of $116.25 million. Coherus Biosciences had a return on equity of 190.82% and a net margin of 33.42%. View Coherus Biosciences' earnings history. What price target have analysts set for CHRS? 9 equities research analysts have issued 1-year price targets for Coherus Biosciences' stock. Their forecasts range from $20.00 to $43.00. On average, they anticipate Coherus Biosciences' stock price to reach $29.78 in the next twelve months. This suggests a possible upside of 63.5% from the stock's current price. View analysts' price targets for Coherus Biosciences. Has Coherus Biosciences been receiving favorable news coverage? News coverage about CHRS stock has trended negative this week, InfoTrie reports. The research firm ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Coherus Biosciences earned a coverage optimism score of -2.9 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future. View the latest news about Coherus Biosciences. Are investors shorting Coherus Biosciences? Coherus Biosciences saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 18,290,000 shares, an increase of 18.6% from the June 15th total of 15,420,000 shares. Based on an average trading volume of 1,780,000 shares, the short-interest ratio is presently 10.3 days. Approximately 28.2% of the company's stock are sold short. View Coherus Biosciences' Current Options Chain. Who are some of Coherus Biosciences' key competitors? Some companies that are related to Coherus Biosciences include Adaptive Biotechnologies (ADPT), Allogene Therapeutics (ALLO), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Ablynx (ABLYF), Halozyme Therapeutics (HALO), Momenta Pharmaceuticals (MNTA), Iovance Biotherapeutics (IOVA), bluebird bio (BLUE), Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Twist Bioscience (TWST), Sorrento Therapeutics (SRNE), Immunovant (IMVT) and SpringWorks Therapeutics (SWTX). View all competitors. What other stocks do shareholders of Coherus Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Coherus Biosciences investors own include Chembio Diagnostics (CEMI), Halozyme Therapeutics (HALO), Exelixis (EXEL), Intelsat (I), Bank of America (BAC), Heron Therapeutics (HRTX), Immunomedics (IMMU), Gilead Sciences (GILD), Iovance Biotherapeutics (IOVA) and Pfizer (PFE). Who are Coherus Biosciences' key executives? Coherus Biosciences' management team includes the following people: Mr. Dennis M. Lanfear, Chairman, Pres & CEO (Age 64)Dr. Jean-Frédéric Viret, Chief Financial Officer (Age 53)Dr. Peter K. Watler, Chief Technical Officer (Age 57)Dr. V. Bryan Lawlis Jr., Science Director, Director & Member of Supervisory Board (Age 67)Mr. Vincent R. Anicetti, Chief Operating Officer (Age 64) What is Coherus Biosciences' stock symbol? Coherus Biosciences trades on the NASDAQ under the ticker symbol "CHRS." Who are Coherus Biosciences' major shareholders? Coherus Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Candriam Luxembourg S.C.A. (0.94%), Peregrine Capital Management LLC (0.63%), Comerica Bank (0.09%), Ziegler Capital Management LLC (0.09%), Foundry Partners LLC (0.08%) and Assenagon Asset Management S.A. (0.07%). Company insiders that own Coherus Biosciences stock include Barbara K Finck, Dennis M Lanfear, James Healy, Jean-Frederic Viret, Mary T Szela, Mats Wahlstrom and Vincent R Anicetti. View institutional ownership trends for Coherus Biosciences. Which institutional investors are selling Coherus Biosciences stock? CHRS stock was sold by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc., Foundry Partners LLC, and Wakefield Asset Management LLLP. Company insiders that have sold Coherus Biosciences company stock in the last year include Dennis M Lanfear, Jean-Frederic Viret, Mary T Szela, Mats Wahlstrom, and Vincent R Anicetti. View insider buying and selling activity for Coherus Biosciences. Which institutional investors are buying Coherus Biosciences stock? CHRS stock was bought by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Comerica Bank, Ziegler Capital Management LLC, Assenagon Asset Management S.A., New York State Teachers Retirement System, Oregon Public Employees Retirement Fund, UBS Group AG, and SG Americas Securities LLC. View insider buying and selling activity for Coherus Biosciences. How do I buy shares of Coherus Biosciences? Shares of CHRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Coherus Biosciences' stock price today? One share of CHRS stock can currently be purchased for approximately $18.21. How big of a company is Coherus Biosciences? Coherus Biosciences has a market capitalization of $1.29 billion and generates $356.07 million in revenue each year. The biotechnology company earns $89.83 million in net income (profit) each year or $1.23 on an earnings per share basis. Coherus Biosciences employs 232 workers across the globe. What is Coherus Biosciences' official website? The official website for Coherus Biosciences is www.coherus.com. How can I contact Coherus Biosciences? Coherus Biosciences' mailing address is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. The biotechnology company can be reached via phone at 650-649-3530 or via email at [email protected] This page was last updated on 8/3/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
